Table 2.

ALK inhibitor sequences and proportions of patients

	n (%) of overall population (N = 410)
1 ALK inhibitor	233 (56.8)
Crizotinib only	205
Alectinib only	20
Ceritinib only	5
Brigatinib only	3
2 ALK inhibitors	144 (35.1)
Crizotinib → ceritinib	59
Crizotinib → alectinib	21
Crizotinib → brigatinib	3
Alectinib →  crizotinib	60
Alectinib → brigatinib	1
3 ALK inhibitors	31 (7.6)
Crizotinib → alectinib →  ceritinib	23
Alectinib → crizotinib →  brigatinib	6
Ceritinib → crizotinib →  brigatinib	2
4 ALK inhibitors	2 (0.5)
Alectinib → crizotinib →  brigatinib →  ceritinib	2

ALK anaplastic lymphoma kinase